OOIR: Observatory of International Research

Papers

(The H4-Index of Blood is 87. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Balancing Monitoring and Access: Optimal Duration of Monitoring for CD19 and BCMA CART Recipients for Lymphoma and Myeloma	1930
Overexpression of Human TLR8 Causes Fatal Anemia in SLE-Prone Mice By Altering the Bone Marrow Erythropoietic Niche	1822
Post-Transplantation Cyclophosphamide for Gvhd Prophylaxis in Related and Unrelated Allogeneic Hematopoietic Cell Transplantation: Study from the SFGM-TC Registry	1023
First Line B+R in Elderly Patients with Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma: A Real-World Experience	511
Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cel	306
Germline Variants in MDM4 Cause a Disorder of p53 Dysregulation and Insufficient Telomere Maintenance	247
Effect of Bruton Tyrosine Kinase Inhibitor on Serologic and Cellular Immune Responses to Recombinant Zoster Vaccine	237
Use of Endpoints in Phase III Randomized Controlled Trials for Acute Myeloid Leukemia over the Last 15 Years: A Systematic Review	234
Real-World Disease Burden, Costs and Resource Utilization of Hospital-Based Care Among Mantle Cell Lymphoma, Waldenström Macroglobulinemia, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia: Dis	220
Effects of Bypassing Hemostatic Agents in the Co-Presence of NXT007, Emicizumab-Based Engineered Bispecific Antibody to Fixa/Fx, Using in Vitro Global Assays: Rough Indicators for Their Concomitant Us	213
Germline MPO Variants Predispose to Myeloid Neoplasia: Potential Mechanisms Suggested By In Vivo and in Vitro Studies	182
Comparison of Characteristics and Laboratory Tests of COVID 19-Hematological Patients from France and Brazil: Identification of Prognostic Driven Profiles	178
Platelets are hot and cold, RhoA is up and down	175
ERG: the good, the bad, and the ugly	169
An AID to follicular lymphoma transformation	166
Unexpected parvovirus B19 infection in a patient with multiple myeloma	162
Disrupting Mitohormesis As a Novel Therapeutic Strategy for Multiple Myeloma (MM) Including Those with High Risk Disease and Proteosome Inhibitor Resistance	162
Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio ≥100	161
Newly Developed Oncolytic Herpes Simplex Viruses Expressing Multiple Immunomodulatory Transgenes Effectively Target AML Cells	155
Serum Proteomic Analyses Suggest That the HMGB1 and Other Inflammatory Pathways Are Operational in MBL and Are Less in Overt CLL	146
The Impact of Revised Definitions for TACO and TRALI on Hemovigilance Reporting	146
Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States	144
Clinical, Cytogenetic, and Molecular Characteristics Analysis in Myelodysplastic Syndromes with Elevated Ferritin Levels	141
Bleeding tendency with corkscrew hair	140
PI3king apart a rare disease with targeted therapy	136

Proton export takes charge of proliferation	134
Peripheral erythrophagocytosis in paroxysmal cold hemoglobinuria	134
A rare glimpse of Fessas bodies in a patient with β-thalassemia major postsplenectomy	133
Breaking T-cell tolerance in the immune system	132
Targeting PKCα decreases iron overload in diabetes	131
Heparin or nonheparin anticoagulants for VITT	129
GADD45A: a key tumor suppressor in AML subtypes	126
Baby steps in managing CVAD-related thrombosis	125
One step at a time	124
An ATLAS to map MRD with peripheral blood	123
Contactless edema via plasmin	119
High-mobility-group protein A1 in MPN progression	118
Waking up exhausted BCMA-specific T cells in myeloma	118
Blast phagocytosis	118
MDM2 inhibition augments GVL effect	118
Renewing your HBO1 subscription	116
Role and timing of chromosome deletions in multiple myeloma	115
Towards a standard of care in transplant for WAS	113
Pediatric B-acute lymphoblastic leukemia presenting with a mass: an underrecognized association	113
Pooled Analysis of First-Line Treatment with Targeted Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Aged 80 Years and Older	112
CSF3R Splicing Regulates Granulopoiesis Via Splice Variant Specific Responses to G-CSF	111
Combined Plasma Fibrinogen and Neutrophil-Lymphocyte Ratio As a Predictive Factor in Patients with Diffuse Large B-Cell Lymphoma	111
Development and Validation of a Novel Prognostic Nomogram Model and a Web-Based Survival Rate Calculator for Diffuse Large B-Cell Lymphoma in the Rituximab Era	111
Real-World Comparison of Time to Next Treatment for Patients with CLL Initiated on First-Line Treatment with Ibrutinib Versus Acalabrutinib	110
Efficacy and Tolerability of Gemcitabine-Based Chemotherapy in Relapsed/Refractory Lymphoma Patients Not Eligible for Stem Cell Transplant	109
Manipulating MEF2C: Discovering Novel Drugs to Target ETP-ALL	109
CREST-UK: CPX-351 Real-World Effectiveness and Safety Study for the Treatment of Newly Diagnosed Therapy-Related AML and AML with Myelodysplasia-Related Changes in the UK	109
Biomarker Association with Hypertension in Mild Versus Severe Sickle Cell Disease Genotypes of a Single Center Cohort, in Comparison with African Americans from the Nhanes Study	109
Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)	107
Clinical Characteristics Associated with Venous Thromboembolism in Patients with Non-APL Acute Myeloid Leukemia	105
Graft-Vs-Host Disease (GvHD) Prophylaxis with Post-Transplant Cyclophosphamide (PTCy) and Thymoglobulin (ATG) Are More Important Determinants of Cytomegalovirus (CMV) Reactivation after Allogeneic Hem	105
Predictors of Efficacy in Chinese Patients with Severe Aplastic Anemia Treated with Eltrombopag and Intensive Immunosupressive Therapy	104
Therapeutic Targeting of Mertk and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia	103
Antiaging for Ph-like ALL: targeting senescence	102
Validating Direct Oral Anticoagulants (DOAC) for Use in Children By the Throm-PED Doac Registry of the International Pediatric Thrombosis Network	102
Herpesvirus Infections of Intestinal Tract in the Patients with Intestinal Graft-Versus-Host Diseases: Laboratory Diagnosis Based on DNA Detection By Real-Time Quantitative PCR in Feces Samples	102
The chromatin accessibility landscape of pediatric AML	101
The Diversity of Long-Term Persistent WT1-Specific Cytotoxic T Lymphocytes after Wilms' Tumor 1 Peptide Vaccination	100
Machine Learning Reveals Patient Phenotypes and Stratifies Outcomes in Chronic Graft-Versus-Host Disease	98
Trial in Progress: A Perspective Study of Pan-Oral Triplet Regimen Pomalidomide, Ixazomib and Dexamethasone in Relapsed or Refractory Myeloma Patients	98
Erythropoiesis Stimulating Agents (ESAS) in Supportive Care of Low-Risk Myelodysplastic Syndromes: Recamds Registry FINAL Results	98
A New Class of Synthetic Type-B Polycyclic Polyprenylated Acylphloroglucinols (PPAP-B) Overcomes Venetoclax-Resistance in Acute Myeloid Leukemia (AML)	97
Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study	97
Cost Effectiveness Analysis of Venetoclax Plus Azacitidine Versus Azacitidine in Newly Diagnosed Adult Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy from a United	97
Novel Home-Based Transfusion Model of Palliative Care in Malignant Hematology	96
Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide	96
Enhanced p53 Activation By Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML	95
Single-Cell RNA Sequencing Unveils the Hallmarks of Populations at Different Stages of HTLV-1 Infection	94
Association of Progression Patterns in Monoclonal Gammopathy of Undetermined Significance (MGUS) with Outcome in Multiple Myeloma: A Cohort Study of over 35 Years	94
Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphom	94

Predicting Platelet Age Using Artificial Intelligence Techniques	93
Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Experience in a Multi-Centre Study	92
Prevalence of Smoldering Multiple Myeloma: Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study	91
A First-in-Human Phase 1 Study of Oral LOXO-338, a Selective BCL2 Inhibitor, in Patients with Advanced Hematologic Malignancies (Trial in Progress)	91
Rapid Clinical Mutation Screening for AML Using the Genexus Platform	90
Synthetic Lethal Interactions with IRAK4 Inhibition in Myeloid Malignancies	89
Impact of Publicly Reported Center Specific Analysis on Patient Selection Practices for Hematopoietic Stem Cell Transplantation	89
Functional Diversification and Dynamics of CAR-T Cells in B-ALL Patients	89
Constructing a Machine Learning-Based Rating Model to Predict the Outcome of GCSF Mobilization of Hematopoietic Stem Cells in Peripheral Blood	88
Characteristics and Clinical Outcomes of Patients with Acute Myeloid Leukemia with TP53 Mutations - a Single Center Experience	88
Sting Activation Improves T-Cell Engaging Immunotherapy of Acute Myeloid Leukemia	88
Phase I / II Study on Infusion of Alloreactive or Ex Vivo il-15 Stimulated Natural Killer Cells after Haploidentical Stem Cell Transplantation in Pediatric Patients with Acute Leukemia (PHINK):	87